Two Sigma Advisers LP Has $6.43 Million Stock Position in Viridian Therapeutics, Inc. (NASDAQ:VRDN)

Two Sigma Advisers LP lessened its position in Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) by 24.6% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 335,569 shares of the company's stock after selling 109,231 shares during the period. Two Sigma Advisers LP owned approximately 0.42% of Viridian Therapeutics worth $6,433,000 at the end of the most recent reporting period.

Several other hedge funds have also recently bought and sold shares of VRDN. FMR LLC increased its stake in shares of Viridian Therapeutics by 6.2% in the fourth quarter. FMR LLC now owns 11,881,912 shares of the company's stock valued at $227,776,000 after purchasing an additional 698,434 shares during the period. Vanguard Group Inc. grew its holdings in Viridian Therapeutics by 4.0% in the 4th quarter. Vanguard Group Inc. now owns 4,595,049 shares of the company's stock worth $88,087,000 after buying an additional 174,952 shares in the last quarter. Deep Track Capital LP increased its position in Viridian Therapeutics by 20.6% in the 4th quarter. Deep Track Capital LP now owns 4,522,741 shares of the company's stock valued at $86,701,000 after acquiring an additional 771,796 shares during the period. Tang Capital Management LLC raised its stake in Viridian Therapeutics by 11.1% during the 4th quarter. Tang Capital Management LLC now owns 2,492,925 shares of the company's stock valued at $47,789,000 after acquiring an additional 250,000 shares in the last quarter. Finally, Alliancebernstein L.P. boosted its position in Viridian Therapeutics by 3.8% during the 4th quarter. Alliancebernstein L.P. now owns 2,286,994 shares of the company's stock worth $43,842,000 after acquiring an additional 84,255 shares during the period.

Viridian Therapeutics Price Performance

Shares of VRDN traded up $0.45 during mid-day trading on Thursday, hitting $13.95. The company's stock had a trading volume of 353,729 shares, compared to its average volume of 1,188,248. The firm has a 50-day moving average price of $13.07 and a 200 day moving average price of $16.63. The stock has a market capitalization of $1.14 billion, a price-to-earnings ratio of -3.23 and a beta of 0.57. The company has a debt-to-equity ratio of 0.04, a current ratio of 18.55 and a quick ratio of 18.55. Viridian Therapeutics, Inc. has a fifty-two week low of $9.90 and a fifty-two week high of $27.20.

Viridian Therapeutics (NASDAQ:VRDN - Get Free Report) last issued its earnings results on Tuesday, May 6th. The company reported ($0.87) earnings per share for the quarter, topping analysts' consensus estimates of ($0.95) by $0.08. The firm had revenue of $0.07 million during the quarter, compared to analysts' expectations of $0.16 million. Viridian Therapeutics had a negative net margin of 85,127.16% and a negative return on equity of 70.12%. The firm's revenue was up .0% compared to the same quarter last year. On average, research analysts predict that Viridian Therapeutics, Inc. will post -4.03 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on VRDN shares. Needham & Company LLC reissued a "buy" rating and set a $36.00 price target on shares of Viridian Therapeutics in a report on Tuesday, May 20th. JMP Securities decreased their target price on shares of Viridian Therapeutics from $42.00 to $38.00 and set a "market outperform" rating for the company in a research report on Wednesday, May 7th. Royal Bank of Canada lowered their target price on shares of Viridian Therapeutics from $46.00 to $45.00 and set an "outperform" rating on the stock in a research note on Wednesday, May 7th. The Goldman Sachs Group dropped their price target on shares of Viridian Therapeutics from $31.00 to $27.00 and set a "buy" rating on the stock in a research report on Wednesday, May 7th. Finally, HC Wainwright reiterated a "buy" rating and issued a $34.00 price objective on shares of Viridian Therapeutics in a report on Wednesday, April 23rd. One research analyst has rated the stock with a hold rating and ten have assigned a buy rating to the stock. According to data from MarketBeat, Viridian Therapeutics presently has an average rating of "Moderate Buy" and an average target price of $36.70.

Viridian Therapeutics Profile

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.